Latest Breaking News On - Celonic group - Page 2 : comparemela.com

By Syndicated Content By Ludwig Burger (Reuters) -CureVac said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected. CureVac said on June 16 its COVID-19 vaccine, known as CVnCoV, proved only 47% effective in an initial trial read-out and that new variants had proved a headwind, denting investor confidence in its ability to take on rival shots.

United statesUnited kingdomRosalba obrienLudwig burgerFranz werner haasEuropean unionEuropean medicines agencyCelonic group of switzerlandLatin americaChief executive officer franz wernerCelonic groupRentschler biopharmaRosalbao brienஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்லுட்விக் பர்கர்